-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49

Benzinga·08/17/2026 16:13:03
Listen to the news
Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $40 to $49.